Premium
Therapeutic Benefit of Chemotherapy and Hormone Therapy Among Estrogen Response Signature‐Positive ER+/PR+/HER2‐ Breast Cancers
Author(s) -
Sandhu Rupninder,
Parker Joel,
Anders Carey,
Coleman William
Publication year - 2015
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.29.1_supplement.926.6
Subject(s) - medicine , oncology , breast cancer , hormone therapy , estrogen , chemotherapy , adjuvant , estrogen receptor , adjuvant therapy , hormonal therapy , cancer , gynecology
ER+/PR+/HER2‐ breast cancers are frequently associated with good outcomes, but some patients experience disease progression/recurrence. We examined disease relapse and relapse‐free survival (RFS) as measures of response to chemotherapy (Chemo), hormone therapy (HT), and Chemo+HT among 182 ER+/PR+/HER2‐ breast cancers (with known molecular subtype) that differentially express a 583‐gene estrogen response signature (ERS). 25 patients received Chemo, 13 received HT, 20 received Chemo+HT, and 124 patients received no adjuvant therapy (surgery only). Overall, ERS+ ER+/PR+/HER2‐ breast cancers have better RFS (62/142, 43% relapse irrespective of therapy) versus ERS‐ ER+/PR+/HER2‐ breast cancers (26/39, 67% relapse irrespective of therapy). Regardless of ERS status, 29/58 (50%) treated patients relapse and 60/124 (48%) untreated patients relapse. However, response to therapy varies according to ERS status among treated patients. ERS+ ER+/PR+/HER2‐ breast cancers show benefit of HT or Chemo+HT – 45/96 (47%) untreated relapse and 10/19 (52%) Chemo relapse versus 3/9 (33%) HT relapse and 4/18 (22%) Chemo+HT relapse. ERS‐ ER+/PR+/HER2‐ breast cancers do not show benefit of Chemo, HT, or Chemo+HT – 15/28 (54%) untreated relapse and 11/11 (100%) treated relapse (irrespective of adjuvant modality). These results suggest that there is value in knowing ERS when treating ER+/PR+/HER2‐ breast cancers.